J. Schellens

2.1k total citations
37 papers, 1.8k citations indexed

About

J. Schellens is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, J. Schellens has authored 37 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 10 papers in Molecular Biology and 9 papers in Pulmonary and Respiratory Medicine. Recurrent topics in J. Schellens's work include Drug Transport and Resistance Mechanisms (7 papers), Cancer therapeutics and mechanisms (6 papers) and Colorectal Cancer Treatments and Studies (5 papers). J. Schellens is often cited by papers focused on Drug Transport and Resistance Mechanisms (7 papers), Cancer therapeutics and mechanisms (6 papers) and Colorectal Cancer Treatments and Studies (5 papers). J. Schellens collaborates with scholars based in Netherlands, United Kingdom and United States. J. Schellens's co-authors include Marc Maliepaard, Jos H. Beijnen, Jaap Verweij, Dick Pluim, Eric K. Rowinsky, Sharyn D. Baker, Ross C. Donehower, L B Grochow, Alex Sparreboom and Hilde Rosing and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Annals of the New York Academy of Sciences.

In The Last Decade

J. Schellens

37 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
J. Schellens Netherlands	20	1.2k	594	275	234	166	37	1.8k
Floris A. de Jong Netherlands	23	1.2k 1.0×	648 1.1×	207 0.8×	331 1.4×	198 1.2×	54	1.9k
J. H. Beijnen Netherlands	20	810 0.7×	412 0.7×	305 1.1×	106 0.5×	110 0.7×	47	1.4k
Mark J. Dresser United States	24	1.3k 1.1×	697 1.2×	517 1.9×	258 1.1×	153 0.9×	49	2.5k
Maki Hasegawa Japan	27	622 0.5×	701 1.2×	250 0.9×	122 0.5×	90 0.5×	68	2.2k
Chun-ling Dai China	16	992 0.8×	695 1.2×	145 0.5×	188 0.8×	137 0.8×	19	1.4k
Alice A. Gibson United States	23	790 0.7×	391 0.7×	261 0.9×	158 0.7×	65 0.4×	46	1.4k
Joseph A. Ware United States	25	999 0.8×	814 1.4×	359 1.3×	327 1.4×	152 0.9×	70	2.2k
Jurjen S. Lagas Netherlands	21	1.2k 1.0×	501 0.8×	385 1.4×	119 0.5×	136 0.8×	29	1.7k
Barry R. Goldspiel United States	31	1.4k 1.2×	1.2k 2.1×	318 1.2×	335 1.4×	193 1.2×	66	3.1k
Willem J. Nooijen Netherlands	14	1.1k 1.0×	343 0.6×	323 1.2×	179 0.8×	95 0.6×	21	1.6k

Countries citing papers authored by J. Schellens

Since Specialization

Citations

This map shows the geographic impact of J. Schellens's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Schellens with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Schellens more than expected).

Fields of papers citing papers by J. Schellens

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Schellens. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Schellens. The network helps show where J. Schellens may publish in the future.

Co-authorship network of co-authors of J. Schellens

This figure shows the co-authorship network connecting the top 25 collaborators of J. Schellens. A scholar is included among the top collaborators of J. Schellens based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Schellens. J. Schellens is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Verheijen, Remy B., et al.. (2017). Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization. Cancer Chemotherapy and Pharmacology. 80(6). 1171–1178. 49 indexed citations

Kerklaan, Bojana Milojkovic, S. Slater, Michael Flynn, et al.. (2016). A phase I, dose escalation, pharmacodynamic, pharmacokinetic, and food-effect study of α2 integrin inhibitor E7820 in patients with advanced solid tumors. Investigational New Drugs. 34(3). 329–337. 21 indexed citations

Juric, Dejan, Martin Schüler, J. Schellens, et al.. (2014). Phase I Study of the Pi3K&Agr; Inhibitor Byl719, As a Single Agent in Patients with Advanced Solid Tumors (Ast). Annals of Oncology. 25. iv150–iv150. 7 indexed citations

Brandsma, Dieta, Bojana Milojkovic Kerklaan, Véronique Dièras, et al.. (2014). Phase 1/2A Study of Glutathione Pegylated Liposomal Doxorubicin (2B3-101) in Patients with Brain Metastases (Bm) from Solid Tumors or Recurrent High Grade Gliomas (Hgg). Annals of Oncology. 25. iv157–iv157. 23 indexed citations

Hasselt, J. G. Coen van, et al.. (2011). Population Pharmacokinetic-Pharmacodynamic Analysis of Trastuzumab-Associated Cardiotoxicity. Clinical Pharmacology & Therapeutics. 90(1). 126–132. 28 indexed citations

Lankheet, Nienke A. G., Christian U. Blank, Henk Mallo, et al.. (2011). Determination of Sunitinib and Its Active Metabolite N-Desethylsunitinib in Sweat of a Patient. Journal of Analytical Toxicology. 35(8). 558–565. 30 indexed citations

Rosing, Hilde, Rutger H.T. Koornstra, Sabine C. Linn, et al.. (2009). Development and validation of a quantitative assay for the analysis of tamoxifen with its four main metabolites and the flavonoids daidzein, genistein and glycitein in human serum using liquid chromatography coupled with tandem mass spectrometry. Journal of Chromatography B. 877(24). 2519–2529. 47 indexed citations

Brouwers, E. E. M., Maaike Söhne, Saskia Kuipers, et al.. (2008). Ciprofloxacin Strongly Inhibits Clozapine Metabolism. Clinical Drug Investigation. 29(1). 59–63. 32 indexed citations

Brouwers, E. E. M., Alwin D. R. Huitema, Kirsten J. M. Schimmel, et al.. (2007). Monitoring of platinum surface contamination in seven Dutch hospital pharmacies using inductively coupled plasma mass spectrometry. International Archives of Occupational and Environmental Health. 80(8). 689–699. 40 indexed citations

10.

Bongard, H.J.G.D. van den, Dick Pluim, Robert C.A.M. van Waardenburg, et al.. (2003). In vitro pharmacokinetic study of the novel anticancer agent E7070: red blood cell and plasma protein binding in human blood. Anti-Cancer Drugs. 14(6). 405–410. 9 indexed citations

11.

Tibben, Matthijs M., Jeany M. Rademaker-Lakhai, James A. Rice, et al.. (2002). Determination of total platinum in plasma and plasma ultrafiltrate, from subjects dosed with the platinum-containing N-(2-hydroxypropyl)methacrylamide copolymer AP5280, by use of graphite-furnace Zeeman atomic-absorption spectrometry. Analytical and Bioanalytical Chemistry. 373(4-5). 233–236. 21 indexed citations

12.

Baker, Sharyn D., Jaap Verweij, Eric K. Rowinsky, et al.. (2002). Role of Body Surface Area in Dosing of Investigational Anticancer Agents in Adults, 1991-2001. JNCI Journal of the National Cancer Institute. 94(24). 1883–1888. 220 indexed citations

13.

Malingré, Mirte M., J. Schellens, Olaf van Tellingen, et al.. (2001). The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients. British Journal of Cancer. 85(10). 1472–1477. 55 indexed citations

14.

Terwogt, Jetske M. Meerum, et al.. (2000). Validated method for the determination of platinum from a liposomal source (SPI-77) in human plasma using graphite furnace Zeeman atomic absorption spectrometry. Fresenius Journal of Analytical Chemistry. 366(3). 298–302. 28 indexed citations

15.

Kerbusch, Thomas, Alwin D. R. Huitema, Jannemieke Ouwerkerk, et al.. (2000). Evaluation of the autoinduction of ifosfamide metabolism by a population pharmacokinetic approach using NONMEM. British Journal of Clinical Pharmacology. 49(6). 555–561. 39 indexed citations

16.

Schellens, J., Marc Maliepaard, Rik J. Scheper, et al.. (2000). Transport of Topoisomerase I Inhibitors by the Breast Cancer Resistance Protein: Potential Clinical Implications. Annals of the New York Academy of Sciences. 922(1). 188–194. 86 indexed citations

17.

Herben, Virginie M.M., Hilde Rosing, W.W. ten Bokkel Huinink, et al.. (1999). Oral topotecan: bioavailability and effect of food co-administration. British Journal of Cancer. 80(9). 1380–1386. 50 indexed citations

18.

Mackean, Melanie, André Planting, Chris Twelves, et al.. (1998). Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer.. Journal of Clinical Oncology. 16(9). 2977–2985. 224 indexed citations

19.

Schellens, J., et al.. (1989). Relationship between the metabolism of antipyrine, hexobarbital and theophylline in patients with liver disease as assessed by a ‘cocktail’ approach. European Journal of Clinical Investigation. 19(5). 472–479. 15 indexed citations

20.

Schellens, J., et al.. (1987). Mephenytoin polymorphism in relation to methylphenytoin phenytoin and phenobarbital hydroxylation. Clinical Pharmacology & Therapeutics. 41(2). 158. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact